CANTOS, 2017 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of canakinumab versus placebo in Stable Post-myocardial Infarction Patients With Elevated hsCRP

        Z

NCT01327846    Am Heart J 2011;162:597-605  



Studied treatment Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months
Control treatment placebo



Patients Stable Post-myocardial Infarction Patients With Elevated hsCRP
Size10066



Blindness double-blind Inclusion period apr 2011 -
Follow-up duration 36 months Centers
Lost to FU geographical localisation
Primary endpoint cardiovascular events Design
PeriodeInclusionapr 2011 -



EndpointX1N1X0N0TE95% CI0,22,01,0

On June the 22th, 2017, the sponsor announced that Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis

Ridker PM, Thuren T, Zalewski A, Libby P Interleukin-1? inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605     [PMID: 21982649]   link to pdf   add to Mendeley  

Links

medpage

press release

ClinicalTrial.gov record NCT01327846



Registering number NCT01327846 (see trial on clinicaltrials.gov)
Code Name

Comment: On June the 22th, 2017, the sponsor announced that Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis